The Company’s innovative new drug is heading to Human Clinical Trials
SHELTON, CT / ACCESSWIRE / December 17, 2019 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), is a development stage nano-biopharmaceutical Company focused on countering viral infections, which has developed a unique, proprietary nanomedicine technology.
Investment timing is one of the most critical concepts related to the world of stock market investing. While its application is important for investments across any and every sector, one particular industry where it is most relevant is the biotech industry. Often, we see biotech companies with minimal revenues that are on the verge of clearing a particular phase of trials for a high-potential drug and once the phase is cleared, their stock price zooms as their market capitalization increases exponentially. Investors entering the stock before the clearance of the phase end up with phenomenal returns. One such biopharmaceutical player that is on the cusp of entering human trials for its highly promising drug candidate is NanoViricides (NYSE American: NNVC).
Key Takeaways from the SmallCapsDaily article:
For more insight into NanoViricides and to continue reading the article, please click here.
About NanoViricides, Inc.
NanoViricides, Inc. is a Connecticut-based biopharma company at the development stage, with proprietary research focused on viral diseases. Founded in 2005, the company has developed its own standout nanomedicine technology called a nanoviricide i.e. a medical agent designed to compel a virus into attaching to an antiviral nanomachine in order to neutralize and destroy the same and prevent it from attaching itself to other cells in the body. The company has its own, state-of-the-art cGMP manufacturing facility and its research is focused on a wide variety of viral diseases such as shingles, herpes simplex, seasonal and potentially-epidemic influenzas and bird flu, HIV/AIDS, cold sores, viral eye diseases, and dengue viruses.
Contact:
SmallCapsDaily
info@smallcapsdaily.com
SOURCE: NanoViricides, Inc.
View source version on accesswire.com:
https://www.accesswire.com/570510/NanoViricides-Inc-Upcoming-Human-Clinical-Trials-Create-Opportunity-for-Innovation
TAMPA, Fla., March 27, 2024 /PRNewswire/ -- Greenway Health, a leading health information technology services provider, announced its strategic…
List Based on an Independent Survey of 25,000 U.S. ResidentsREMOTE-FIRST COMPANY/NEW YORK--(BUSINESS WIRE)--#NextGenHealthcare--NextGen Healthcare, a…
Fuller will help drive the growth and innovation of strategic communications firmCARLSBAD, Calif.--(BUSINESS WIRE)--#AppointmentNews--Ford Hutman…
Microsoft Azure customers worldwide can now purchase Lightbeam’s care orchestration technology suite directly from the…
General Catalyst leads funding round joined by .406 Ventures, Valtruis, Mass General Brigham Ventures, and…
PHOENIX--(BUSINESS WIRE)--Creative Medical Technology Holdings, Inc., (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a…